Zacks Research Analysts Lift Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities research analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of West Pharmaceutical Services in a note issued to investors on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $1.50 per share for the quarter, up from their previous estimate of $1.44. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q3 2025 earnings at $1.61 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.93 EPS and Q1 2027 earnings at $1.44 EPS.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The company had revenue of $698.00 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same quarter in the previous year, the firm posted $1.56 EPS. The firm’s revenue was up .4% compared to the same quarter last year.

Other equities analysts have also issued research reports about the company. KeyCorp cut their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Evercore ISI started coverage on West Pharmaceutical Services in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research report on Friday, February 14th. Stephens upgraded West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, April 21st. Finally, StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $332.50.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $216.38 on Friday. The stock has a market cap of $15.55 billion, a PE ratio of 32.34, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. The business has a 50-day simple moving average of $214.89 and a 200-day simple moving average of $275.07. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $356.14.

Institutional Trading of West Pharmaceutical Services

Several hedge funds have recently modified their holdings of WST. Whipplewood Advisors LLC acquired a new stake in West Pharmaceutical Services in the fourth quarter valued at $25,000. Zions Bancorporation National Association UT acquired a new stake in West Pharmaceutical Services in the first quarter valued at $25,000. Quarry LP acquired a new stake in West Pharmaceutical Services in the first quarter valued at $27,000. Retirement Wealth Solutions LLC acquired a new stake in West Pharmaceutical Services in the fourth quarter valued at $34,000. Finally, Centricity Wealth Management LLC acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $35,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services’s payout ratio is currently 13.19%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.